108 related articles for article (PubMed ID: 9132431)
1. [Optimal antibacterial chemotherapy for infectious diseases associated with hematological malignancies].
Sakamoto M
Kansenshogaku Zasshi; 1997 Jan; 71(1):72-82. PubMed ID: 9132431
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro].
Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K
Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of cefozopran for infections associated with hematological malignancies].
Sasai Y; Iwai T; Tamura A; Nakazawa N; Ueda Y; Kaneko H; Horiike S; Yokota S; Taniwaki M; Kashima K; Misawa S; Tsuda S; Ohgawara Y
Jpn J Antibiot; 1998 Aug; 51(8):501-8. PubMed ID: 9836122
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy with imipenem/cilastatin for severe infections accompanied by malignant hematological disorders].
Fujii Y; Inoue Y; Hiroshige Y; Kaku K; Kaneko T
Jpn J Antibiot; 1993 Mar; 46(3):259-68. PubMed ID: 8510323
[TBL] [Abstract][Full Text] [Related]
5. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
[TBL] [Abstract][Full Text] [Related]
6. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of panipenem/betamipron as a second line chemotherapy in severe infections associated with hematological disorders].
Nakazawa N; Okamoto T; Kobayashi M; Iwai T; Sasai Y; Tamura A; Horiike S; Yokota S; Taniwaki M; Kashima K; Misawa S; Tuda S; Ohkawara Y
Jpn J Antibiot; 1998 Aug; 51(8):509-20. PubMed ID: 9836123
[TBL] [Abstract][Full Text] [Related]
8. [Laboratory and clinical studies on imipenem/cilastatin sodium plus amikacin sulfate in patients with severe infections complicating hematological disorders].
Hotta T; Morishima Y; Saito H; Kodera Y; Hirabayashi N; Tanaka M; Mizuno H; Suzuki H; Kato Y; Morishita Y
Jpn J Antibiot; 1991 May; 44(5):515-28. PubMed ID: 1880931
[TBL] [Abstract][Full Text] [Related]
9. [The in vitro antibacterial activity of cefozopran against clinically isolated bacteria].
Higurashi Y; Okuzumi K; Yoneyama A; Nakahara K
Jpn J Antibiot; 1997 Dec; 50(12):907-16. PubMed ID: 9545668
[TBL] [Abstract][Full Text] [Related]
10. [Effect of imipenem/cilastatin combined with vancomycin for MRSA infection].
Fukabori T; Mizobuchi K; Nakamura M; Takizawa H; Takashina R; Fujita Y
Jpn J Antibiot; 1997 Apr; 50(4):299-305. PubMed ID: 9192247
[TBL] [Abstract][Full Text] [Related]
11. [A comparative study of imipenem/cilastatin sodium BID vs QID in the treatment of infections associated with hematopoietic disorders].
Sawae Y; Niho Y; Okamura T; Murakawa M; Teshima T; Fujisaki T; Ikeda K; Kozuru M; Uike N; Katsuno M
Jpn J Antibiot; 1994 Oct; 47(10):1318-28. PubMed ID: 7807693
[TBL] [Abstract][Full Text] [Related]
12. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1995)].
Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kawaguchi H; Shimizu Y; Matsumiya H; Saito A; Terai T; Inoue H; Nakadate T; Ito C; Yosida T; Tanno Y; Ohno I; Nishioka K; Arakawa M; Igarashi K; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Touyama M
Jpn J Antibiot; 1997 May; 50(5):421-59. PubMed ID: 9212366
[TBL] [Abstract][Full Text] [Related]
13. [Nephrotoxicity and drug interaction of vancomycin (2)].
Toyoguchi T; Nakagawa Y
Nihon Yakurigaku Zasshi; 1996 May; 107(5):225-35. PubMed ID: 8690304
[TBL] [Abstract][Full Text] [Related]
14. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
[TBL] [Abstract][Full Text] [Related]
15. Bacteriological efficacy of nafcillin and vancomycin alone or combined with rifampicin or amikacin in experimental meningitis due to methicillin-susceptible or -resistant Staphylococcus aureus.
Sato K; Lin TY; Weintrub L; Olsen K; McCracken GH
Jpn J Antibiot; 1985 Aug; 38(8):2155-62. PubMed ID: 3852897
[TBL] [Abstract][Full Text] [Related]
16. Sepsis associated with hematological malignancies: prophylaxis of Pseudomonas aeruginosa sepsis.
Sakamoto M; Saruta K; Nakazawa Y; Shindo N; Maezawa H; Yoshikawa K; Yoshida M; Shiba K; Sakai O; Saito A
Kansenshogaku Zasshi; 1996 Feb; 70(2):116-22. PubMed ID: 8851383
[TBL] [Abstract][Full Text] [Related]
17. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
18. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2002)].
Shimada K; Nakano K; Igari J; Oguri T; Ikemoto H; Mori T; Yokouchi H; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Okada S; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Nakata K; Nakatani T; Inagawa H; Kudo K; Kobayashi N; Tanaka T; Kobayashi H; Goto H; Kawai S; Takeda H; Sumitomo M; Matsushima T; Niki Y; Kohno S; Miyazaki Y; Yanagihara K; Hirakata Y; Matsuda J; Nasu M; Hiramatsu K; Suga M; Tosaka M
Jpn J Antibiot; 2004 Jun; 57(3):213-45. PubMed ID: 15376784
[TBL] [Abstract][Full Text] [Related]
19. [In vitro combination effect of pazufloxacin with various antibiotics against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus].
Maekawa M; Takahashi K; Takahata M; Minami S
Jpn J Antibiot; 2002 Aug; 55(4):440-5. PubMed ID: 12378872
[TBL] [Abstract][Full Text] [Related]
20. [In vitro combination effect of vancomycin and carbapenems against carbapenem-resistant MRSA].
Sato S; Miura T; Kudo E; Kudo Y; Saitoh Y; Kimpara I; Tsujino M; Kudo H
Jpn J Antibiot; 1997 Aug; 50(8):711-6. PubMed ID: 9339397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
